OrphoMed Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 8
Employees
  • Latest Deal Type
  • Debt - PPP
  • Investors
  • 5

OrphoMed General Information

Description

Developer of dimer therapeutics platform designed for the treatment of Irritable Bowel Syndrome with Diarrhea, Opioid Bowel Dysfunction and pain. The company's platform focuses is on developing therapies for irritable bowel syndrome with diarrhea (IBS-D), acute and chronic pain and cystic fibrosis, enabling patients to get a first line treatment from Diarrhea, Opioid Bowel Dysfunction and pain.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
  • 50 Francisco Street
  • Suite 245
  • San Francisco, CA 94133
  • United States
+1 (415) 000-0000

OrphoMed Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OrphoMed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Debt - PPP 30-Apr-2020 0000 Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 24-May-2017 0000 0000 0000 Completed Clinical Trials - Phase 2
To view OrphoMed’s complete valuation and funding history, request access »

OrphoMed Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view OrphoMed’s complete cap table history, request access »

OrphoMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of dimer therapeutics platform designed for the treatment of Irritable Bowel Syndrome with Diarrhea, Opioid Bo
Biotechnology
San Francisco, CA
8 As of 2020
0000
000000000 - 0000

00000000

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea co
000000000000000
Cambridge, MA
000 As of 0000
00000
000000000 00000

000000 0

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000000000000
Foster City, CA
00000 As of 0000
00.000
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OrphoMed Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ironwood Pharmaceuticals Corporate Backed or Acquired Cambridge, MA 000 00000 000000000 00000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000&0
000000 000000000 Formerly Angel backed Delray Beach, FL 00 000.00 000000000 000.00
0000000 Formerly VC-backed Fremont, CA 000 00000 000000000 00000
00000 000000 Formerly VC-backed Solana Beach, CA 0 0000 00000000000 0000
You’re viewing 5 of 11 competitors. Get the full list »

OrphoMed Executive Team (10)

Name Title Board Seat Contact Info
Gregory Beyer Chief Financial Officer
Nikhilesh Singh Ph.D Co-Founder, Chief Scientific Officer & Board Member
Frank Steinberg Co-Founder
Lisa Turner Vice President, Clinical Operations
Virginia Sanders Ph.D Vice President, Preclinical Development & Program Management
You’re viewing 5 of 10 executive team members. Get the full list »

OrphoMed Board Members (9)

Name Representing Role Since
Arthur Pappas Pappas Capital Board Member 000 0000
Blake Wu Self Board Member 000 0000
Gary Phillips MD Self Chief Executive Officer, President & Board Member 000 0000
Kenneth Widder MD OrphoMed Executive Chairman 000 0000
Michael Chao MD Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

OrphoMed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OrphoMed Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Mario Family Fund Other Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
Pappas Capital Venture Capital Minority 000 0000 000000 0
Relativity Healthcare Partners Venture Capital Minority 000 0000 000000 0
Takeda Ventures Corporate Venture Capital Minority 000 0000 000000 0
To view OrphoMed’s complete investors history, request access »